# The Efficacy and Safety of Rifaximin Treatment

> **NCT05786859** · EARLY_PHASE1 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 124 (estimated)

## Conditions studied

- Liver Failure, Acute on Chronic
- Hepatic Encephalopathy
- HBV
- Hepatitis B
- Rifaximin
- Effect of Drug

## Interventions

- **DRUG:** Rifaximin 200 mg
- **OTHER:** Standard Treatment without Rifaximin

## Key facts

- **NCT ID:** NCT05786859
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-09
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786859, "The Efficacy and Safety of Rifaximin Treatment". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05786859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*